Blood clot drug taken by millions of Americans may cause deaths from strokes, heart attack
A new report questions the efficacy of a drug approved by the FDA to help precent heart attack and stroke in people with a ...
Medscape9h
New Investigation Casts Doubt on Landmark Ticagrelor Trial
New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...
Investigation raises new concerns over landmark trial for top selling anti-platelet drug
An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain ...
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
ICR Healthcare is coordinating meetings on the Company’s behalf. To schedule a meeting with Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer, please send ...
News Medical1d
Controversy surrounds landmark anti-platelet drug trial
An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the ...
BMJ1d
Doubts over landmark heart drug trial: ticagrelor PLATO study
A top selling antiplatelet drug has never quite shaken off doubts about its advantage over cheaper rivals. With generic versions of ticagrelor about to launch, Peter Doshi takes a fresh look at the ...
Daily3d
Prasugrel Outperforms Ticagrelor in Reducing Mortality and Stroke in Routine Acute Coronary Syndrome Care: JAMA
Germany: A recent cohort study published in JAMA Network Open has shed light on the comparative outcomes of ticagrelor and ...
manilatimes3d
CytoSorbents Announces Rights Offering
PRINCETON, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life ...